#### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

1. (original) A compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:

$$R^2$$
 $R^3$ 
 $R^3$ 
 $R^4$ 
 $R^5$ 
 $R^5$ 

wherein

 $R^1$  is selected from  $C_{6-10}$ aryl and  $C_{2-6}$ heteroaryl, wherein said  $C_{6-10}$ aryl and  $C_{2-6}$ heteroaryl are optionally substituted with one or more groups selected from -R, -NO<sub>2</sub>, -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1-6}$ alkyl; and

 $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are, independently, selected from hydrogen,  $C_{1-6}$ alkyl, and  $C_{3-6}$ cycloalkyl, wherein said  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl are optionally substituted with one or more groups selected from -R, -NO<sub>2</sub>, -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1-6}$ alkyl.

2. (original) A compound according to claim 1,

wherein R<sup>1</sup> is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl, wherein R<sup>1</sup> is optionally

substituted with one or more groups selected from C<sub>1-6</sub>alkyl, halogenated C<sub>1-6</sub>alkyl, -NO<sub>2</sub>, -CF<sub>3</sub>, C<sub>1-6</sub> alkoxy, chloro, fluoro, bromo, and iodo;

R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are, independently, C<sub>1-3</sub>alkyl or halogenated C<sub>1-3</sub>alkyl; R<sup>5</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, and C<sub>3-6</sub>cycloalkyl, wherein said C<sub>1-6</sub>alkyl and C<sub>3-6</sub>cycloalkyl are optionally substituted with one or more groups selected from C<sub>1-6</sub>alkyl, halogenated C<sub>1-6</sub>alkyl, -NO<sub>2</sub>, -CF<sub>3</sub>, C<sub>1-6</sub> alkoxy, chloro, fluoro, bromo, and iodo.

3. (original) A compound according to claim 1,

wherein  $R^1$  is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; pyrrolyl; and thiazolyl, wherein  $R^1$  is optionally substituted with one or more groups selected from  $C_{1-6}$ alkyl, halogenated  $C_{1-6}$ alkyl, -NO<sub>2</sub>, -CF<sub>3</sub>,  $C_{1-6}$  alkoxy, chloro, fluoro, bromo, and iodo;

 $R^2$ ,  $R^3$ , and  $R^4$  are, independently,  $C_{1-3}$ alkyl or halogenated  $C_{1-3}$ alkyl; and  $R^5$  is hydrogen.

4. (original) A compound according to claim 1,

wherein R<sup>1</sup> is selected from phenyl, pyridyl, thienyl, furyl, imidazolyl, pyrrolyl, and thiazolyl;

R<sup>2</sup> and R<sup>3</sup> are ethyl;

R<sup>4</sup> is C<sub>1-3</sub>alkyl; and

R<sup>5</sup> is hydrogen.

5. (original) A compound according to claim 1, wherein the compound is selected from:

[3-[[4-[(diethylamino)carbonyl]phenyl][1-(2-thienylmethyl)-4-piperidinylidene]methyl]phenyl]- carbamic acid, methyl ester;

[3-[[4-[(diethylamino)carbonyl]phenyl][1-(2-furanylmethyl)-4-piperidinylidene]methyl]phenyl]- carbamic acid, methyl ester;

[3-[[4-[(diethylamino)carbonyl]phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]phenyl]-carbamic acid, methyl ester;

methyl 3-{{4-[(diethylamino)carbonyl]phenyl}{1-(1,3-thiazol-4-ylmethyl)piperidin-4-ylidene]methyl}phenylcarbamate;

methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[1-(1,3-thiazol-5-ylmethyl)piperidin-4-ylidene]methyl}phenylcarbamate;

and pharmaceutically acceptable salts thereof.

#### 6. (cancelled)

- 7. (currently amended) The use of a compound according to any one of claims 1-5 in the manufacture of a medicament A method for the therapy of pain, anxiety or functional gastrointestinal disorders, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 1.
- 8. (currently amended) A pharmaceutical composition comprising a compound according to any one of claims 1-5 claim 1 and a pharmaceutically acceptable carrier.
- 9. (currently amended) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5 claim 1.
- 10. (currently amended) A method for the therapy of functional gastrointestinal disorders in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5 claim 1.
- 11. (original) A process for preparing a compound of formula I, comprising:

$$R^2$$
 $R^3$ 
 $R^3$ 
 $R^5$ 
 $R^5$ 
 $R^5$ 

reacting a compound of formula II with X-C(=O)-O-R<sup>4</sup>:

$$R^2$$
 $R^3$ 
 $R^3$ 
 $R^4$ 
 $R^5$ 
 $R^1$ 

wherein

X is Cl, Br or I;

 $R^1$  is selected from  $C_{6-10}$ aryl and  $C_{2-6}$ heteroaryl, wherein said  $C_{6-10}$ aryl and  $C_{2-6}$ heteroaryl are optionally substituted with one or more groups selected from -R, -NO<sub>2</sub>, -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1-6}$ alkyl; and

 $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are, independently, selected from hydrogen,  $C_{1\text{-}6}$ alkyl, and  $C_{3\text{-}6}$ cycloalkyl, wherein said  $C_{1\text{-}6}$ alkyl and  $C_{3\text{-}6}$ cycloalkyl are optionally substituted with one or more groups selected from -R, -NO<sub>2</sub>, -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1\text{-}6}$ alkyl.

# 12. (original) A compound of formula III:

$$\mathbb{R}^2$$
 $\mathbb{R}^3$ 
 $\mathbb{R}^3$ 
 $\mathbb{R}^5$ 
 $\mathbb{R}^5$ 
 $\mathbb{R}^5$ 
 $\mathbb{R}^5$ 
 $\mathbb{R}^5$ 

wherein

 $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are, independently, selected from hydrogen,  $C_{1\text{-}6}$ alkyl, and  $C_{3\text{-}6}$ cycloalkyl, wherein said  $C_{1\text{-}6}$ alkyl and  $C_{3\text{-}6}$ cycloalkyl are optionally substituted with one or more groups selected from -R, -NO<sub>2</sub>, -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1\text{-}6}$ alkyl; and

R<sup>6</sup> is selected from -H and -C(=O)-O-C<sub>1-6</sub>alkyl.

## 13. (original) A process for preparing a compound of formula I, comprising:

$$R^2$$
 $R^3$ 
 $R^4$ 
 $R^5$ 
 $R^5$ 

reacting a compound of formula IV with R<sup>1</sup>-CHO or R<sup>1</sup>CH<sub>2</sub>-X:

wherein

X is Cl, Br or I;

 $R^1$  is selected from  $C_{6-10}$ aryl and  $C_{2-6}$ heteroaryl, wherein said  $C_{6-10}$ aryl and  $C_{2-6}$ heteroaryl are optionally substituted with one or more groups selected from -R, -NO<sub>2</sub>, -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1-6}$ alkyl; and

 $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are, independently, selected from hydrogen,  $C_{1\text{-}6}$ alkyl, and  $C_{3\text{-}6}$ cycloalkyl, wherein said  $C_{1\text{-}6}$ alkyl and  $C_{3\text{-}6}$ cycloalkyl are optionally substituted with one or more groups selected from -R, -NO<sub>2</sub>, -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1\text{-}6}$ alkyl.

14. (new) A method for the therapy of pain, anxiety or functional gastrointestinal disorders, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 2.

15. (new) A method for the therapy of pain, anxiety or functional gastrointestinal disorders, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 3.

- 16. (new) A method for the therapy of anxiety, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 1.
- 17. (new) A method for the therapy of anxiety, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 2.
- 18. (new) A method for the therapy of anxiety, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 3.
- 19. (new) A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier.
- 20. (new) A pharmaceutical composition comprising a compound according to claim 3 and a pharmaceutically acceptable carrier.